FILGOTINIB, A SELECTIVE JAK1 INHIBITOR, INDUCES CLINICAL REMISSION IN PATIENTS WITH MODERATE-TO-SEVERE CROHN?S DISEASE: FINAL ANALYSIS OF THE PHASE 2 FITZROY STUDY

Severine Vermeire  ¹     Stefan Schreiber  ²     R. Petryka  ³     Tanja Kuehbacher  ⁴     Xavier Hebuterne  ⁵     Xavier Roblin     Maria Klopocka     Eugen-Adrian Goldis     Maria Wisniewska Jarosinska     Andrey Baranovsky     Robert Sike     Kremana Stoyanova     Chantal Tasset     Annegret Van der Aa     Pille Harrison    
¹ University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium
² Universität Kiel UKSH Medizinische Abt. I, UKSH, Kiel, Germany
³ Gastroenterol., NZOZ Vivamed, Warszawa, Poland, Warsaw, Poland
⁴ Asklepios Wet Hospital Clinic of Internal Medicine, Dept of gastroenterology, Hamburg, Germany
⁵ Hospital Arche 2, Hepatogastroenter

Conference
UEG Week 2016

Citation
United European Gastroenterology Journal; 2016: 2 (Supplement 1)